Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma

Modern Pathology

Volumn 24, Issue 5, 2011, Pages 638-645

  Shih, Ie Ming ^a   Nakayama, Kentaro ^b   Wu, Gang ^c   Nakayama, Naomi ^b   Zhang, Jinghui ^c   Wang, Tian Li ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b SHIMANE UNIVERSITY   (Japan)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

gene amplification; ovarian cancer; serous carcinoma

Indexed keywords

DNA; PACLITAXEL; PROTEIN NAC1; RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CANCER RECURRENCE; COPY NUMBER VARIATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE LOCUS; GENETIC ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION;

CHROMOSOMES, HUMAN, PAIR 19; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; REPRESSOR PROTEINS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 79955622235     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.230     Document Type: Article

References (31)

1. Cho KR, Shih IM. Ovarian cancer. Annu Rev Pathol Mech Dis 2009;4:287-313.
2. Kuo K, Mao T, Feng Y, et al. DNA copy number profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res 2010;16:1997-2008.
3. Kuo KT, Guan B, Feng Y, et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res 2009;69:4036-4042.
4. Nakayama K, Nakayama N, Jinawath N, et al. Ampli-con profiles in ovarian serous carcinomas. Int J Cancer 2007;120:2613-2617. (Pubitemid 46651282)
5. Schraml P, Schwerdtfeger G, Burkhalter F, et al. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol 2003;163:985-992. (Pubitemid 37040134)
6. Meinhold-Heerlein I, Bauerschlag D, Hilpert F, et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 2005;24:1053-1065. (Pubitemid 40313882)
7. Mayr D, Kanitz V, Anderegg B, et al. Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays. Am J Clin Pathol 2006;126: 101-109. (Pubitemid 44025077)
8. Nowee ME, Snijders AM, Rockx DA, et al. DNA profiling of primary serous ovarian and fallopian tube carcinomas with array comparative genomic hybridization and multiplex ligation-dependent probe amplification. J Pathol 2007;213:46-55.
9. Wang TL, Maierhofer C, Speicher MR, et al. Digital karyotyping. Proc Natl Acad Sci USA 2002;99: 16156-16161. (Pubitemid 35462765)
10. Nakayama K, Nakayama N, Davidson B, et al. Homo-zygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biol Ther 2006;5:630-634. (Pubitemid 44024717)
11. Shih Ie M, Sheu JJ, Santillan A, et al. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci USA 2005;102: 14004-14009. (Pubitemid 41377693)
12. Park JT, Li M, Nakayama N, et al. Notch-3 gene amplification in ovarian cancer. Cancer Res 2006;66: 6312-6318.
13. Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 2007;23:657-663. (Pubitemid 46554715)
14. Reich M, Liefeld T, Gould J, et al. GenePattern 2.0. Nat Genet 2006;38:500-501.
15. Wang TL, Diaz Jr LA, Romans K, et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci USA 2004;101:3089-3094.
16. Nakayama K, Nakayama N, Davidson B, et al. A BTB/ POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci USA 2006;103:18739-18744. (Pubitemid 44913480)
17. Farley J, Smith LM, Darcy KM, et al. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Res 2003;63:1235-1241. (Pubitemid 36348700)
18. Cheng JQ, Godwin AK, Bellacosa A, et al. AKT2, a putative oncogene encoding a member of a subfamily of protein- serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992;89:9267-9271.
19. Choi JH, Sheu JJ, Guan B, et al. Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res 2009;69:1407-1415.
20. Chaudhary K, Deb S, Moniaux N, et al. Human RNA polymerase II-associated factor complex: dysregulation in cancer. Oncogene 2007;26:7499-7507. (Pubitemid 350207717)
21. Wang JRS, Chu J, Shen X, et al. A protein interaction network for pluripotency of embryonic stem cells. Nature 2006;444:364-368. (Pubitemid 44764111)
22. Jinawath N, Vasoontara C, Yap KL, et al. NAC-1, a potential stem cell pluripotency factor, contributes to paclitaxel resistance in ovarian cancer through inactivating Gadd45 pathway. Oncogene 2009;28:1941-1948.
23. Ishibashi M, Nakayama K, Yeasmin S, et al. A BTB/ POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for taxol resistance in ovarian cancer. Clin Cancer Res 2008;14:3149-3155.
24. Hogarty MD, Brodeur GM. Gene amplification in human cancers: biological and clinical significance. In: Vogelstein B, Kinzler Kw (eds). The Genetic Basis of Human Cancer, 2 edn. McGraw-Hill: New York, 2002, pp 115-128.
25. Abhiman S, Iyer LM, Aravind L. BEN: a novel domain in chromatin factors and DNA viral proteins. Bioinfor-matics 2008;24:458-461. (Pubitemid 351256287)
26. Nakayama K, Nakayama N, Wang T-L, et al. NAC-1 controls cell growth and survival by repressing transcription of Gadd45GIP1, a candidate tumor suppressor. Cancer Res 2007;67:8058-8064. (Pubitemid 47395140)
27. Davidson B, Berner A, Trope CG, et al. Expression and clinical role of the bric-a-brac tramtrack broad com-plex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions. Hum Pathol 2007;38:1030-1036. (Pubitemid 46908824)
28. Ishikawa M, Nakayama K, Yeasmin S, et al. NAC1, a potential stem cell pluripotency factor expression in normal endometrium, endometrial hyperplasia and endometrial carcinoma. Int J Oncol 2010;36: 1097-1103.
29. Yeasmin S, Nakayama K, Ishibashi M, et al. Expression of the bric-a-brac tramtrack broad complex protein NAC-1 in cervical carcinomas seems to correlate with poorer prognosis. Clin Cancer Res 2008;14:1686-1691. (Pubitemid 351469452)
30. Ueda SM, Yap KL, Davidson B, et al. Expression of fatty acid synthase depends on NAC1 and is associated with recurrent ovarian serous carcinomas. J Oncol 2010;2010:285191.
31. Park JT, Chen X, Trope CG, et al. Notch3 overexpres-sion is related to the recurrence of ovarian cancer and confers resistance to Carboplatin. Am J Pathol 2010; 177:1087-1094.